April 22, 2022
Article
March 14, 2022
The FDA based its approval on OlympiA trial data, which show the PARP inhibitor has the ability to reduce risks of invasive breast cancer recurrence, second cancers, and death, and to improve overall survival.
February 09, 2022
Video
An interactive, moderated discussion among clinicians, health system executives, payers and health policy influencers discussing how to overcome the barriers to broader adoption of biosimilars in the United States.
December 22, 2021
Neil Minkoff, MD, provides a preview of an upcoming AJMC video series discussing the challenges of alopecia areata for patients and caregivers and the impact it has on quality of life.
December 17, 2021
Kathy Oubre, MS, discusses key takeaways from the cancer immunotherapy (CIT) roundtable and changes to her approach to CIT management in the future.
December 15, 2021
Stuart Genschaw, MBA, discusses how his practice approaches cancer immunotherapy (CIT) management and the potential future pathways of care.
August 16, 2021
Neil Minkoff; Natasha Mesinkovska, MD; and Brett King, MD, PhD discuss the diagnosis and disease assessment in alopecia areata along with clinical considerations.
July 20, 2021
April 14, 2021
March 18, 2021
